Stribild (elvitegravir;cobicistat;emtricitabine;tenofovir disoproxil)
- Region
- 🇪🇺 EU
- Active substance
- elvitegravir;cobicistat;emtricitabine;tenofovir disoproxil
- Company
- Gilead Sciences Ireland UC
- Status
- Authorised
- Therapeutic area
- HIV Infections
- EU approval
- Fri 24 May 2013
- Application
- EMEA/H/C/002574
- ATC
- J05AR09
- Official record
- www.ema.europa.eu
Indication
Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.
Regulatory milestones
No milestones recorded in the last year.
Follow Stribild
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.